Transgene SA Total Assets
Transgene SA total assets. Based on the latest financial reports, Transgene SA (TNG) holds total assets worth €138.83 Million EUR (≈ $162.30 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see TNG market cap for the company's overall valuation and market capitalisation.
Total Assets of Transgene SA (1997–2025)
Total assets of Transgene SA from 1997 to 2025. This chart illustrates how Transgene SA's total assets have evolved over time, based on quarterly financial data. See Transgene SA share price for real-time trading data and today's change.
Transgene SA - Asset Composition Analysis
Transgene SA Total Assets Breakdown (December 2025)
Transgene SA total assets breakdown as of December 2025. Transgene SA's total assets of €138.83 Million consist of 84.8% current assets and 15.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 4.8% |
| Accounts Receivable | €3.68 Million | 2.7% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €49.00K | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (1997–2025)
This chart illustrates how Transgene SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Transgene SA's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Transgene SA's current assets represent 84.8% of total assets in 2025, an increase from 58.5% in 1997.
- Cash Position: Cash and equivalents constituted 4.8% of total assets in 2025, down from 47.3% in 1997.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1997.
- Asset Diversification: The largest asset category is accounts receivable at 2.7% of total assets.
Transgene SA Competitors by Total Assets
Key competitors of Transgene SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Transgene SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.62 | 1.48 | 2.25 |
| Quick Ratio | 9.62 | 1.48 | 2.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €105.45 Million | €6.68 Million | €17.06 Million |
Transgene SA - Advanced Valuation Insights
This section examines the relationship between Transgene SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.01 |
| Latest Market Cap to Assets Ratio | 1.76 |
| Asset Growth Rate (YoY) | 229.2% |
| Total Assets | €138.83 Million |
| Market Capitalization | $244.86 Million USD |
Valuation Analysis
Above Book Valuation: The market values Transgene SA's assets above their book value (1.76x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Transgene SA's assets grew by 229.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Transgene SA (1997–2025)
The table below shows the annual total assets of Transgene SA from 1997 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €138.83 Million ≈ $162.30 Million |
+229.17% |
| 2024-12-31 | €42.17 Million ≈ $49.31 Million |
-6.73% |
| 2023-12-31 | €45.22 Million ≈ $52.86 Million |
-31.94% |
| 2022-12-31 | €66.44 Million ≈ $77.67 Million |
-34.76% |
| 2021-12-31 | €101.84 Million ≈ $119.06 Million |
+19.17% |
| 2020-12-31 | €85.45 Million ≈ $99.90 Million |
-26.00% |
| 2019-12-31 | €115.48 Million ≈ $135.00 Million |
+6.39% |
| 2018-12-31 | €108.54 Million ≈ $126.90 Million |
+7.60% |
| 2017-12-31 | €100.87 Million ≈ $117.93 Million |
-17.96% |
| 2016-12-31 | €122.95 Million ≈ $143.74 Million |
+21.89% |
| 2015-12-31 | €100.87 Million ≈ $117.93 Million |
-28.44% |
| 2014-12-31 | €140.95 Million ≈ $164.79 Million |
+12.00% |
| 2013-12-31 | €125.85 Million ≈ $147.13 Million |
-21.57% |
| 2012-12-31 | €160.46 Million ≈ $187.60 Million |
-17.11% |
| 2011-12-31 | €193.58 Million ≈ $226.32 Million |
-13.46% |
| 2010-12-31 | €223.69 Million ≈ $261.51 Million |
+126.72% |
| 2009-12-31 | €98.66 Million ≈ $115.35 Million |
-22.10% |
| 2008-12-31 | €126.65 Million ≈ $148.06 Million |
-1.30% |
| 2007-12-31 | €128.31 Million ≈ $150.01 Million |
+293.54% |
| 2006-12-31 | €32.60 Million ≈ $38.12 Million |
+27.85% |
| 2004-12-31 | €25.50 Million ≈ $29.81 Million |
-44.34% |
| 2003-12-31 | €45.82 Million ≈ $53.57 Million |
-31.49% |
| 2002-12-31 | €66.88 Million ≈ $78.19 Million |
-22.61% |
| 2001-12-31 | €86.42 Million ≈ $101.03 Million |
+80.27% |
| 2000-12-31 | €47.94 Million ≈ $56.04 Million |
-28.33% |
| 1999-12-31 | €66.89 Million ≈ $78.20 Million |
-21.14% |
| 1998-12-31 | €84.82 Million ≈ $99.16 Million |
+181.28% |
| 1997-12-31 | €30.15 Million ≈ $35.25 Million |
-- |
About Transgene SA
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) posi… Read more